Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment

OBJECTIVE: To compare 2‐year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). METHODS: Patients prescribed NTZ, FTY, or DMF at the Rocky Mountain MS Center at University of Colorado were identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Brandi L., Nair, Kavita V., Sillau, Stefan, Corboy, John R., Vollmer, Timothy, Alvarez, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389745/
https://www.ncbi.nlm.nih.gov/pubmed/30847358
http://dx.doi.org/10.1002/acn3.700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389745/
https://www.ncbi.nlm.nih.gov/pubmed/30847358
http://dx.doi.org/10.1002/acn3.700

Ejemplares similares